CCL3 and neuropathy: Importantly, it is postulated that autoantibodies against CCL3 are biomarkers of type 1 diabetes development [96]; therefore, research on the impact of the modulation of this chemokine on the development of neuropathy should undoubtedly be continued due to its potential therapeutic benefits.